tinal metastases; pulmonary nodule L ung cancer causes more cancer-related deaths in the United States than any other malignancy.
Two facts account for this disturbing observation. The incidence of lung cancer in both men and women has progressively increased in recent years. Treatment of lung cancer remains largely ineffective. The overall 5-year survival rate for patients with lung cancer may be as low as 7 percent to 14 percent. The best survival rates are found in the subgroup of patients with lung cancer with surgically resectable tumors. Clinicians, therefore, are vitally interested in recognizing lung cancer early and determining surgical resectability accurately.
Computed tomography (CT) was introduced into clinical practice in the 1970s as an exciting new method for imaging the thorax. Since then, clinicians have come to rely heavily on CT for evaluating potentially malignant chest lesions and the intrathoracic spread of lung cancer. A survey of thoracic surgeons in 1986 revealed that more than one third of these surgeons order CT routinely for all patients with lung cancer and 62 percent more selectively obtain CT scans.1 Despite the frequency at which clinicians obtain CT scans, it is still unclear what role CT plays in the treatment of patients with suspected and known lung cancers. Clinicians are especially concerned with how well CT performs in distinguishing benign from malignant solitary pulmonary nodules (SPN) and in staging the primary tumor (T) and regional node (N) extent of lung cancer (Table 1 ). In *From the Dartmouth Medical School and Pulmonary Section, VA Hospital, White River Junction, Vermont. this review, the role CT should play in evaluating SPNs and assessing the T and N stages of lung cancer will be critically evaluated.
DISTINGUISHING BENIGN FROM MALIGNANT NODULES
An appealing way to distinguish between benign and malignant SPNs would be to rely on some combination of radiographic features seen on either the Colice) standard frontal and lateral chest radiograph (CXR) or linear tomography. Although there are no classic radiographic features of lung cancer, size is an obvious consideration. Nodules smaller than 8 mm are usually considered benign, and nodules larger than 3 cm are more often malignant. There are other radiographic features strongly suggesting the benign nature of an SPN. The most reliable of these radiographic features seem to be documented absence of growth of the SPN over a 2-year period and substantial calcification in either a central, diffuse, laminated, or popcorn pattern. Other variables considered include nodule shape, edge definition, satellite lesions, and cavitation. Unfortunately, evaluation of these radiographic features on standard roentgenograms may often be subjective. In 1980, Siegelman et a12 suggested that CT could be used to distinguish between benign and malignant nodules in a quantitative fashion. Because CT is more sensitive than standard radiographic techniques in detecting calcification and the extent of calcification found on CT can be expressed quantitatively as a density, Siegelman's group postulated that an SPN with density numbers suggesting extensive calcification would be most probably benign. The nodules they studied that were dense (>164 Hounsfield units) did indeed prove to be benign.2 Others found similar results.
Soon after these promising initial reports, the reproducibility of densitometry results was questioned. A variety of technical and geometric variables were found to preclude obtaining consistent CT densitometry results not only in different CT machines, but even with the same CT machine repeatedly over time. The major technical variables affecting CT densitometry are the CT algorithm used to reconstruct the CT density distribution, slice thickness, and kilovoltage. There are also geoinetric variables related to the patient, such as patient size, nodule size, nodule position in the thorax, and tissue density surrounding the nodule. Concern over standardization issues led Zerhouni and colleagues3 to develop a reference phantom for quantitative analysis of SPNs. This phantom would serve as a calibration standard for either different CT machines or the same CT machine over time. A nodule density higher than that of the phantom would suggest benignity.
Numerous studies have described the ability of CT densitometry to identify nodules that are most probably benign (Table 2 ). In interpreting the results of these studies, several important points concerning CT densitometry have to be considered. First, as discussed by Swensen et al,4 a suitable density for the standard phantom has not been established. The phantom nodule used in the original multicenter study evaluating its effectiveness was equivalent to 264 Hounsfield units,5 a value considerably higher than that used in earlier studies. The reason for choosing this density was to minimize misdiagnosis of malignant lesions as benign. However, later studies probably used phantoms with considerably lower reference densities. To ensure uniform acceptance of a standard phantom, its density must be established in a nonarbitrary fashion. Second, SPNs with a density lower than that of the reference phantom were classified as indeterminant because of the extensive overlap between benign and malignant nodule densities in this range. A substantial number of benign nodules have low densities (Table 2) . Third, there are numerous methodologic limitations in these studies. Different machines were used among studies. Often, different CT machines were used in the same study, presumably reflecting the introduction of more sophisticated equipment over time. Techniques for performing CT studies, especially slice thickness, often varied. It is not clear that CT scan thickness was appropriately adjusted for nodule diameter in these studies. It is also not clear whether use of the phantom could accommodate all of these variations. Fourth, the nature of the SPNs was not always verified histologically and clinical follow-up varied. Fifth, selection criteria for which patients were included in the studies were not always made clear. Screening studies, such as fluoroscopy and linear tomography, were often used to select patients for CT densitometry.
Although the phantom was an exciting technological step forward for CT, radiologists quickly became skeptical of its value. In a large multicenter study evaluating the phantom, the authors stated that "interpretation of thin section CT scans cannot be purely quantitative, and no immutable CT number can be defined to distinguish benign from malignant nodules."5 As a consequence of this hesitancy to rely solely on densitometry, radiologists have evolved a hybrid approach, using both quantitative and qualitative features of the CT scan, to distinguish benign from possibly malignant SPNs. The quantitative feature is comparison of the nodule density with that of the reference phantom. The qualitative aspects of CT have been adapted from earlier work with standard radiographs and linear tomography. Because CT can more accurately visualize the SPN than either of these two radiographic techniques, it allows better assessment of the size, shape, edge definitions, and internal characteristics of the SPN. Siegelman's group6 was the first to incorporate qualitative features of the SPN, determined by thin-section highresolution CT (HRCT), into criteria also including CT densitometry for identifying benign nodules. The key features used by this group were maximal diameter of the SPN, margin characteristics, distribution and extent of nodule calcification, and presence of fat within the nodule. Other groups used a similar approach (Table 3 ).
It appears that both techniques, CT densitometry alone and the hybrid approach incorporating thinsection HRCT to qualitatively assess the SPN and the CT reference phantom to quantitatively measure density, are quite accurate in labeling SPNs as benign. With CT densitometry alone (Table 2) , only two malignant nodules were misclassified as benign out of a total group of 145 benign nodules (1.4 percent). The hybrid approach (Table 3 ) misclassified 12 malignancies as benign out of 359 (3.3 percent). Current radiologic practice has evolved to accept the high likelihood that these CT techniques accurately identify benign SPNs. Radiologists may suggest that biopsy and surgical intervention be avoided in these CT-identified benign nodules while growth characteristics are assessed over time (the wait-and-watch strategy). In a small number of cases, CT may establish a benign diagnosis, eg, round atelectasis, arterial-venous malformation, hamartoma, etc, with certainty.
The appropriateness of the wait-and-watch approach to CT-identified benign SPNs, intuitively advocated by radiologists, has been supported by mathematical modeling techniques. Kunstaetter et a17 and Cummings and colleagues8 used decision analysis to compare three different strategies, wait-and-watch, biopsy by either transtracheal needle aspirate or fiberoptic bronchoscopy, and immediate surgery, for managing a SPN. In both analyses, if the probability of malignancy were below 3 percent, the wait-and-watch strategy provided the longest calculated life expectancy. Nodules identified as benign by CT densitometry or the hybrid approach have a probability of malignancy in this range.
Although CT techniques seem to be effective in accurately identifying benign SPNs, they are not as reliable in identifying malignant SPNs. Nodules that do not meet the criteria for benignity are classified as indeterminant. Indeterminant nodules are more frequently malignant, but a substantial number are benign (Tables 2 and 3) .'Decision analysis studies indicate that the immediate surgery option yields the highest calculated life expectancies only if the probability of malignancy is quite high, possibly above 85 percent.7'8 The published studies do not clearly show that an indeterminant diagnosis from CT provides an estimated probability of malignancy high enough to support following this option. More recent work, however, suggests that malignancy can be ascertained from CT with a greater degree of certainty by more careful attention to the internal characteristics of the SPN, axial multiplanar reconstruction of CT studies to assess the relationship of the SPN to pulmonary veins, evaluation of the SPN contrast enhancement, and presence of an air bronchogram within the nodule. Another possible method for more accurately identifying malignant SPNs is to incorporate CT features and clinical parameters into formulas based on Bayes' theorem. Cummings et a19 advocated the use of the likelihood ratio form of Bayes' theorem, using such simple clinical variables as patient age and smoking history, to estimate the probability of malignancy in an SPN. The only radiologic parameter used in this study was diameter of the SPN. More recent studies using this type of mathematical approach have increased the number of clinical and radiologic variables used in their calculations and have substantially improved their accuracy rate in distinguishing benign from malignant SPNs. Results from CT were considered, but apparantly thin-section HRCT and CT densitometry were included only infrequently.
Even though thin-section HRCT and CT densitometry are helpful in more clearly identifying a small group of SPNs as highly likely to be benign, clinicians should still be cautious in applying this information to an individual patient. Decision analysis studies suggest that the degree of certainty provided by a benign CT diagnosis is sufficient to favor a wait-andwatch approach to the nodule, but the benefit is only marginal, a few days difference in calculated life expectancy compared with more aggressive strategies. When different management strategies result in such similar calculated outcomes, patient preference becomes critical in choosing a course of action. Furthermore, even if a wait-and-watch approach is adopted, it still mandates careful periodic reassessment of the SPN.
An unresolved question is whether and/or how'CT should be integrated into an overall strategy for evaluating SPNs. Special CT techniques should not be routinely used in the initial assessment of an SPN. With most nodules, management decisions can be made reasonably from information provided by standard radiographic techniques and the clinical history. Assessment from standard radiographs of growth rate, calcification, and edge margins should be the first diagnostic step. If the standard CXR or linear tomography shows either absence of growth for more than 2 years or dense, diffuse, central, laminated, or popcorn calcification, the nodule can safely be considered benign without CT. Alternatively, if these radiographic techniques show that the nodule has a spiculated edge or cavitation, it should be considered indeterminant without CT. Reasonable estimates of the probability of malignancy in a nodule may also be obtained by using derivations of Bayes' theorem and clinical and standard radiographic findings.
It is unclear from the available literature how large a subgroup of SPNs cannot be managed with the above approach. If CT were to be included as another intermediate diagnostic test before biopsy, the medical community should be reassured that this would be a cost-effective approach. There are several reasons suggesting that CT for SPNs may not be cost-effective. Special CT techniques may be expensive. Thin-section HRCT and CT densitometry can generally classify only a small proportion of SPNs, probably less than a third, as benign. Even in these nodules with a very high probability of benignity, the estimated survival advantage for the wait-and-watch approach seems to be small.
A parallel concern for clinicians evaluating an SPN is whether CT should be used to detect other parenchymal nodules. It is clear that CT is more sensitive than standard tomography for detecting nodules.
Mitchell et al'0 reviewed the CT scans of a large heterogenous group of patients with proven lung cancer and found that more than a quarter of these scans revealed nodules not seen on standard CXRs. There is reasonable information available, however, indicating that CT in a patient with an SPN will only rarely detect additional nodules. Multiple primary lung carcinomas are rare. A recent study showed that CT revealed no additional nodules in a group of 36 patients with Ti, NO, MO disease. Kunitoh patients who underwent surgical resection of lung cancer. Only three patients in this group had additional parenchymal lesions detected by preoperative CT. '1 In summary, management decisions regarding most SPNs can be made reasonably using information obtained from the clinical evaluation and standard CXR techniques. Special CT procedures should be reserved for the occasional patient with either equivocal or lacking data and in whom further evidence favoring benignity for the SPN would alter the clinical approach. Routine use of CT to screen patients with SPNs for additional parenchymal nodules is not appropriate.
IDENTIFYING ENDOBRONCHIAL ABNORMALITIES
Thin-section HRCT has proved to be a useful method for visualizing the bronchial tree. In normal subjects, most segmental bronchi and even subsegmental bronchi can be seen quite well. The lingular bronchi are probably the most difficult to identify consistently. These encouraging findings led Naidich and colleagues'2 and others to apply CT to evaluate abnormalities of the bronchial tree in various disease states, eg, bronchogenic carcinoma, adenoma, tuberculous bronchial stenosis, hemoptysis, and atelectasis. Because CT performed well in identifying bronchial tree abnormalities in these preliminary studies, several groups directly compared CT with fiberoptic bronchoscopy (FOB) for detecting bronchial involvement in lung cancer. Although Colice et al'3 reported only moderate sensitivity and specificity for CT, others showed that CT had similar accuracy to FOB in identifying sites of bronchial involvement by lung cancer.
A safe, convenient, and accurate noninvasive technique for evaluating the bronchial tree, such as CT, might provide benefits for the clinician managing lung cancer in three separate ways. First, lung cancer staging requires an assessment of bronchial tree involvement. Submucosal spread of tumor along the proximal airways or unsuspected contralateral endobronchial disease in most cases precludes surgical resection of the primary tumor. Little information is available on how well CT performs in outlining the submucosal proximal extent of disease spread. A disturbing observation has been that biopsy of a carina appearing normal to the bronchoscopist may yield submucosal tumor in a small percentage of patients with lung cancer. It is not clear that CT would be able to detect such an abnormality. Rarely, contralateral endobronchial disease may occur and may be missed by CT. Because contrast agents were not infused during CT in this study, it may have been difficult to distinguish nodes from contiguous vascular structures. However, even with the use of intravenous contrast, experienced radiologists may have difficulty in identifying nodes within certain highly vascular mediastinal regions, eg, the aortopulmonary area. It is important to remember that detection of mediastinal nodes by CT depends not only on the technical characteristics of the scan itself and the ability of the radiologist to interpret the scan, but also on the adequacy of mediastinal evaluation at mediastinoscopy or thoracotomy. The more extensive the mediastinal dissection, the more likely the surgeon will find nodes not seen on CT.
Computed tomographic scans performed in subjects without lung cancer or granulomatous disease frequently reveal mediastinal lymph nodes. Nodes measured in these subjects in the transverse plane are usually smaller than 10 mm, with only a few larger than 10 mm. Normal lymph node size seems to vary by nodal region. Autopsy studies have shown that the largest nodes in normal subjects are found close to the hilum in regions 7, 4, and lOr (Fig 2) . The maximal normal short-axis diameter for nodes in region 7 Node#2 0/ FIGURE 3. Computed tomographic images are taken in the transverse plane. Lymph nodes that run in the cephalad-caudad direction will have their short axis oriented in the CT transverse plane. The long axis of these nodes will be more difficult to measure. Note that lymph nodes not running in a true cephaladcaudad direction will be sliced obliquely by the CT image. This is shown by comparing node 1 and node 2 in the diagram. Even though these nodes are the same size, because of node 2's oblique orientation, its short-axis and long-axis measurements on CT will be different from those of node 1.
CT for Distinguishing Benign From Malignant Nodes
Because CT is a noninvasive imaging technique, it cannot provide direct histologic or cytologic evidence of malignant spread to mediastinal nodes. Nodal involvement by cancer can be inferred only from the size and structural features of CT visualized nodes. The most commonly used criteria for malignant nodal involvement is an enlarged node. The shortaxis diameter of the node is usually the preferred indicator of pathologic enlargement for several reasons. The long-axis and short-axis diameter measurements will be influenced by the orientation of the node relative to the transverse plane of the CT image (Fig 3) . Because mediastinal nodes tend to run in a cephaladcaudad direction, the long axis of these nodes would be less likely to be oriented in the CT transverse plane than the short axis. The coefficient of variation for short-axis diameter measurements is indeed less than for long-axis diameter measurements. The short-axis diameter also correlates better with node volume than the long-axis diameter18 and appears to be more accurate in distinguishing malignant from benign nodes than total cross-sectional nodal area.
The size threshold usually relied on for the upperlimit normal size of mediastinal node short-axis diameter is 10 mm. This limit is based on the CT studies in normal subjects and autopsy studies that showed that normal mediastinal nodes are infrequently larger than 10 mm in diameter. However, these studies also demonstrated that some benign nodes will be larger than this normal threshold. Many studies have confirmed that there is a substantial false-positive rate for CT staging of mediastinal nodes and, surprisingly, have shown that there is a similarly high false-negative rate. Just as enlarged nodes may be benign, a normal-sized node may contain metastatic tumor. Dales and colleagues19 performed a meta-analysis of the studies published between 1980 and 1988 that used CT for mediastinal staging and concluded that the overall sensitivity, specificity, and accuracy for these studies were about 80 percent. More recent studies have yielded similar results. Dales et al19 also analyzed which individual study variables might favor improved accuracy. Increasing the size threshold for an abnormal node seems to reduce the false-positive rate somewhat, but does not clearly improve overall accuracy. Improved CT technology was associated with an improved accuracy. Studies using a fourth-generation CT scanner, a scan time of less than 4 s, a scan thickness of less than 1 cm, and a scan spacing of less than 1 cm had overall sensitivity, specificity, and accuracy rates of 83 percent to 84 percent. 19 Other techniques have been used to improve the accuracy of CT Colice) trend. By improving CT technology, considering the number of enlarged mediastinal nodes, and adjusting the size threshold of an abnormal node by mediastinal region and location of the primary tumor, CT accuracy for mediastinal staging can be increased. This is achieved by improving specificity without sacrificing sensitivity. However, CT studies of mediastinal staging must be interpreted with caution. These studies tended to exclude patients with surgically unresectable disease. For instance, clinicians intuitively believe that patients with an abnormal mediastinum on CXR have an unacceptably high rate of unresectable mediastinal disease. Consequently, they might not obtain a chest CT scan. Furthermore, patients with extensive mediastinal disease on CT might not be sent for an invasive diagnostic procedure to confirm cancer spread. In both these situations, a higher true-positive to false-positive ratio for CT scans would be expected. Excluding these patients will, therefore, artifactually alter CT operating characteristics. Because studies of consecutive patients with lung cancer that include both CT and histologic verification are generally not available, currently published CT operating characteristics for mediastinal staging should be accepted only as approximations. These CT studies have also not taken into account the effect lung inflammation associated with the carcinoma, eg, postobstructive pneumonia, might have on mediastinal node size. Recent work suggests that such inflammation may be an important stimulus for node enlargement.2627 Clinicians rarely consider how well the standard CXR performs in distinguishing benign from malignant mediastinal nodes. Criteria for subcarinal node enlargement on CXR include increased subcarinal density, an abnormal azygoesophageal recess, and an obscured medial wall of the right mainstem bronchus and bronchus intermedius. When these criteria are used to evaluate how well the standard CXR performs in detecting subcarinal adenopathy in patients with enlarged nodes found on CT, CT appears to be more accurate. However, the specificity of CXR for subcarinal adenopathy is quite good. 28 This observation points out important differences in the operating characteristics of CT and CXR (Table 4). Numerous authors have found that CT is better at detecting enlarged mediastinal nodes than CXR. Nodes must be substantially larger to be detected by CXR than CT. However, minimally enlarged nodes seen on CT but not CXR may not necessarily be malignant. Consequently, the false-positive rate for CT is higher than CXR. Conversely, the false-negative rate for CXR is lower than CT Fig 2) . The N2 and N3 designations refer to different extents of mediastinal disease. Patients with N2 disease have tumor in ipsilateral mediastinal and subcarinal lymph nodes, while N3 disease encompasses disease in contralateral, scalene, and supraclavicular nodes. As N stage progresses, resectability becomes less likely and overall prognosis worsens.
Although the N system of mediastinal staging is Bronchoscopy with transbronchial needle aspiration (TBNA) may prove to be a less expensive and safer approach than mediastinoscopy for providing this same information,3' but whether a positive TBNA for malignancy has the same prognostic significance as a diagnostic mediastinoscopy is presently not clear. Other surgical groups strongly believe that mediastinoscopy is not an appropriate screening technique, because surgical resectability of mediastinal disease can only be assessed at thoracotomy.
An alternative view is that CT may be a useful noninvasive screening method for determining the need for mediastinoscopy. If no abnormal nodes were seen on CT, thoracotomy would be performed. If abnormal nodes were found, mediastinoscopy or TBNA directed by the CT results would be used as the intermediate step. An argument in support of this approach is the implicit belief that CT results can improve the results of mediastinoscopy and TBNA by guiding the operator toward enlarged nodes. Stronger support for this approach comes from recent studies. Cybulsky et a132 raise the intriguing possibility that in patients with mediastinal metastases, the subgroup with enlarged nodes on CT have a worse prognosis for surgical cure. Daly and colleagues33 found that in patients with mediastinal disease discovered at thoracotomy, but with a benign mediastinum on prethoracotomy CT, the chances for curative resection were good.
At present, clinical studies directly comparing the various mediastinal staging strategies are not available. However, mathematical modeling techniques, ie, decision analysis, have been used to examine what role CT might play in staging the mediastinum in patients with lung cancer. Black et al34 evaluated the role of CT in patients with clinical TI, NO, MO tumors and found that CT did not substantially affect calculated life expectancy. Malenka and colleagues35 compared multiple strategies using various combinations of CT, mediastinoscopy, and bronchoscopy with TBNA for mediastinal staging. They also found that strategies using CT did not lead to an improved life expectancy. This finding, however, was probably expected because the analysis required that mediastinal nodal disease be verified histologically. In a subsequent study,36 this same group showed that basing therapeutic decisions solely on CT findings resulted in a worse life expectancy than found for strategies relying on invasive procedures for histologic verification of nodal disease.
Several the probability that an abnormal node identified by CT is malignant depends on both the operating characteristics of the CT scan and the prevalence of mediastinal disease in the study population. An abnormal node on CT in a patient with a high likelihood of mediastinal metastases will most probably be malignant, whereas an abnormal node in a patient with a low likelihood of such metastases will more probably be benign. The overall prevalence of mediastinal metastases in patients with newly recognized lung cancer can reasonably be estimated at about 40 percent. However, the prevalence rate varies markedly in subgroups of patients with lung cancer.
A simple and reasonably reliable method for categorizing prevalence of mediastinal metastases is examining the CXR. The CXR findings that have the greatest bearing on the incidence of mediastinal node disease are interpretation of the mediastinum as either normal or abnormal, location of the primary tumor in either the central or peripheral lung field, and size of the primary tumor. The positive predictive value of an abnormal mediastinum on routine CXR for metastases to the mediastinum is so high, that a CT scan, whether its results are positive or negative, will do little to alter the very high probability that the patient does indeed have mediastinal nodal disease. Many authors have stated that performing a CT in a patient with an abnormal mediastinum on CXR adds little to the evaluation of the patient. In patients with a normal mediastinum on CXR the prevalence of mediastinal disease is lower for patients with peripheral primary tumors than central lesions and for small peripheral tumors than large ones. Most studies with few exceptions have shown that CT is rarely helpful in identifying metastatic mediastinal nodes in small peripheral lesions. In these cases, the CT false-positive rate is probably more of a hindrance in the evaluation of these patients than the true-positive rate is of importance. For patients with either a large peripheral tumor or a centrally located cancer and a normal mediastinum on CXR, the prevalence of mediastinal disease is probably intermediate.
These observations raise an intriguing point. Decision analysis studies have provided important insights into the limitations of using CT for mediastinal node staging. The value of using CT to improve the diagnostic accuracy of subsequent invasive diagnostic techniques has not been proved. The accuracy of CT for distinguishing resectable from nonresectable mediastinal disease has not been established. Furthermore, by identifying specificity and prevalence of mediastinal disease as the two key variables influencing the value of noninvasive mediastinal staging techniques, these decision analysis studies question the value of added information provided by CT beyond that available from the CXR. Because CT does not clearly perform better than standard CXR in either of these two variables, clinical decisions about evaluating the mediastinum might reasonably be based on interpretation of the CXR alone. For instance, patients with a high expected prevalence of mediastinal metastases, eg, those with an abnormal mediastinum on CXR or certain clinical manifestations, would not need CT for staging. If either mediastinoscopy or TBNA verify mediastinal metastases, curative resection is unlikely in these patients.
Conversely, for patients with a low expected prevalence of mediastinal metastases, eg, those with a small, peripheral tumor and a normal mediastinum on CXR, the critical issue is not whether mediastinal metastases are present, but whether they would be resectable. In these patients, because CT cannot reliably predict resectability of malignant nodes, the mediastinum should be carefully evaluated at thoracotomy for the presence and resectability of nodal metastases. Patients with a normal mediastinum on CXR and either a central tumor or a large peripheral tumor probably have an intermediate prevalence of mediastinal metastases. The performance characteristics of CT are not sufficiently good enough to either absolutely exclude or confirm mediastinal spread of disease in these cases. Again, evaluation of the mediastinum requires invasive testing.
In summary, the performance characteristics of CT for identifying malignant mediastinal nodes have been well described. Although there are encouraging trends indicating improvement in the accuracy of CT for mediastinal metastases, decision analysis studies suggest that CT at present should not be incorporated into strategies for mediastinal staging. The additional information provided by CT over that available in the standard CXR is not sufficient to justify its expense. Evaluating how CT should be incorporated into a comprehensive strategy for assessing the extent and resectability of mediastinal metastases in patients with lung cancer should be a high priority for future research.
CT FOR DETECTING INVASION OF CONTIGUOUS STRUCTURES
Numerous CT criteria have been proposed for identifying local invasion of contiguous structures by primary lung cancer. Unfortunately, consensus has not been reached over which, if any, of these criteria are useful for this purpose. Computed tomography visualizes pleural effusions well, but the presence of pleural fluid is a nonspecific finding. Pleural effusions may develop in various ways in lung cancer, including secondary to atelectasis, postobstructive pneumonia, and lymphatic obstruction. Only the presence of malignant cells in pleural fluid indicates unresectability. Computed tomographic findings consistent with parietal pleura and local chest wall invasion require that the primary tumor adjoin the chest wall and that there be some combination of either rib destruction, extension of a soft-tissue mass into the chest wall, increased density of extrapleural fat, an obtuse angle between the primary tumor and the chest wall, greater than 3-cm contact of tumor with pleura, an increased ratio of tumor pleural contact to tumor diameter, or thickened pleura. Evaluating the operating characteristics of these CT Computed tomographic evaluation of direct mediastinal invasion by tumor is plagued by problems similar to those described above for identifying parietal pleura invasion. Studies have used incompletely stated criteria to exclude patients with nonresectable conditions, criteria have varied among studies, and study sizes have been occasionally small. Computed tomographic findings used to identify mediastinal invasion include the primary tumor contiguous with the mediastinum and any of such findings as interdigitation of the tumor with the mediastinal tissues, an obtuse angle at the junction of the tumor and the mediastinum, and indentations, notching, encasement, tapering, truncation, or scalloping of mediastinal vessels or bronchi. Even studies using multiple criteria, such as more than a 3-cm contact between tumor and mediastinum, a contact of the tumor with more than one quarter the circumference of the descending aorta, and absence of a mediastinal fat plane separating the tumor from mediastinal structures, have not proved to Colice) resonance imaging (MRI) in this regard. The multiplanar capability of MRI allows for direct imaging of the superior sulcus tumor in the coronal and sagittal planes, allowing better assessment of the cephalad tumor extent. Magnetic resonance imaging also allows better delineation of the brachial plexus and the spinal cord and more clearly demonstrates the relationship of the superior sulcus tumor to nearby vessels. [43] [44] [45] In summary, CT criteria are not well established for distinguishing unresectable from resectable invasion of the parietal pleura, diaphragm, pericardium, and mediastinum. Resectability should be based on the surgeon's assessment at thoracotomy. For tumors of the superior sulcus, MRI is better suited to evaluate preoperative extent of disease than CT.
CONCLUSION
Computed tomography is a remarkable technique for visualizing structures within the thorax. Intensive interest over the past decade has been focused on using CT to evaluate suspected and known lung cancer. Unfortunately, despite efforts by many investigators, it is still not entirely clear how CT should be used to detect and manage bronchogenic carcinoma. Further technological refinements are not sufficient. Careful experimentation must be directed toward establishing strategies for using CT to distinguish benign from malignant chest lesions and to stage and manage the intrathoracic components of lung cancer. These strategies should include estimates of cost-effectiveness as well as clinical reliability.
